Author: Rikke Hedegaard Jensen1, René Ernst Nielsen2, Gustav Bizik3
Affiliation: <sup>1</sup> Department of Health Science and Technology, Aalborg University, Aalborg, Denmark.
<sup>2</sup> Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; Department of Psychiatry - Aalborg University Hospital, Aalborg, Denmark.
<sup>3</sup> Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; Department of Psychiatry - Aalborg University Hospital, Aalborg, Denmark. Electronic address: g.bizik@rn.dk.
Conference/Journal: J Affect Disord
Date published: 2024 Sep 18
Other:
Volume ID: 368 , Pages: 487-492 , Special Notes: doi: 10.1016/j.jad.2024.09.082. , Word Count: 229
Background:
Treatment outcomes of patients who had received T-PEMF as an augmenting therapy at Aalborg University Hospital, Aalborg, Denmark, was evaluated.
Methods:
Patients diagnosed with unipolar depression or bipolar disorder who had received a self-administered 8-week T-PEMF series between November 2019 and April 2023 were included. Data were retrieved from the patients' records. The primary outcome was the Hamilton Rating Scale for Depression 17-item version (HAMD17), both as a continuous measure and with proportions of response and remission reported.
Results:
A total of 57 patients (65.1 % females, 86.0 % unipolar depression, mean age, 48 ± 14 years) were included. Duration of current depressive episode was almost equally divided for <2 years (38.6 %), 2-5 years (38.6 %) and > 5 years (22.8 %). HAM-D17 decreased significantly from baseline (20.8 (SD: 3.3)) to week 8 (14.5 (SD: 6.2), p < 0.001). An episode duration of 2-5 years was associated with lower odds of response on HAM-D6 (adjusted OR = 0.15, 95 % CI: 0.03; 0.96, p < 0.05) and self-rated HAM-D6 (adjusted OR = 0.09, 95 % CI: 0.01; 0.99, p = 0.05) when compared to an episode duration <2 years.
Limitations:
This study is limited by a lack of a control group, limited controlling of confounders, small sample sizes, and an attrition rate of 29.8 % for the primary outcome.
Conclusion:
T-PEMF reduced depressive symptoms in a real-world clinical setting including patients with both unipolar depression and bipolar disorder. Receiving T-PEMF within the first 2 years of the depressive episode was associated with an improved outcome.
Keywords: Real-world data; Transcranial pulsating electromagnetic fields; Treatment-resistant depression.
PMID: 39303885 DOI: 10.1016/j.jad.2024.09.082